Anti-GM1 IgA antibodies in Guillain-Barré syndrome

Amjad Ilyas, Francis A. Mithen, Zi Wei Chen, Stuart D. Cook

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Serum anti-GM1 IgA antibodies were detected in 15 of 53 (28%) patients with the acute Guillain-Barré syndrome (GBS) and in one of 26 (4%) patients with other neurological diseases. Although nine GBS patients had anti-GM1 IgA titers of 1 : 200 or less, six patients had titers of 1 : 800 or more. Some GBS patients with anti-GM1 IgA antibodies also had antibodies against GD1b or GM2 or both. The presence of markedly elevated anti-GM1 IgA was associated with a poor clinical outcome at 6 and 12 months following onset of the GBS. The possible pathogenetic role of anti-GM1 IgA antibodies remains to be established.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalJournal of Neuroimmunology
Issue number1
StatePublished - Jan 1 1992

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


  • Enzyme-linked immunosorbent assay
  • G ganglioside
  • Guillain-Barré syndrome
  • Immunoglobulin A
  • Thin-layer chromatogram-overlay technique

Fingerprint Dive into the research topics of 'Anti-G<sub>M1</sub> IgA antibodies in Guillain-Barré syndrome'. Together they form a unique fingerprint.

Cite this